{
    "clinical_study": {
        "@rank": "97484", 
        "arm_group": [
            {
                "arm_group_label": "A - docetaxel", 
                "arm_group_type": "Active Comparator", 
                "description": "75 mg/m2 docetaxel day 1, 1-hour intravenous, every three weeks"
            }, 
            {
                "arm_group_label": "B - lurbinectedin (PM01183)", 
                "arm_group_type": "Experimental", 
                "description": "7.0 mg flat dose PM01183, day 1, 1-hour intravenous, every three weeks"
            }, 
            {
                "arm_group_label": "C - gemcitabine + lurbinectedin (PM01183)", 
                "arm_group_type": "Experimental", 
                "description": "800 mg/m2 gemcitabine / 3 mg flat dose PM01183 both on day 1 and day 8, 30-minutes gemcitabine/1-hour PM01183 intravenous, every three weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in\n      comparison to docetaxel for the treatment of unresectable non-small cell lung cancer\n      (NSCLC)patients"
        }, 
        "brief_title": "A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Unresectable Non-Small Cell Lung Cancer (NSCLC)", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "A randomized-controlled, three-arm, phase II study of lurbinectedin (PM01183) alone or in\n      combination with gemcitabine and a control arm with docetaxel as second-line treatment in\n      unresectable non-small cell lung cancer (NSCLC)patients to evaluate the antitumor activity\n      as progression-free survival at four months (PFS4) of PM01183 alone or in combination with\n      gemcitabine as  using single agent docetaxel as a reference in the control arm as current\n      standard of care and to analyze overall survival (OS), overall survival rate at 1-year\n      (OS12), duration of response (DR), antitumor activity, as response rate (RR), safety and\n      efficacy profiles of PM01183 alone and in combination with gemcitabine, to be preliminary\n      compared with docetaxel, patients' quality of life (QoL), pharmacokinetics (PK) of PM01183,\n      pharmacokinetic/pharmacodynamic (PK/PD)correlation and pharmacogenomics (PGx)to explore\n      potential correlations between clinical outcomes and molecular parameters found in tumor and\n      blood samples"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed unresectable NSCLC\n\n          -  Patients must have failed one prior line of CT-based therapy for unresectable disease\n\n          -  Age between 18 and 75 years\n\n          -  Eastern Cooperative Oncology Group (ECOG)performance status (PS) \u2264 1\n\n          -  Adequate hematological, renal, metabolic and hepatic function\n\n          -  At least three weeks since the last prior therapy, at least four weeks since\n             completion of any prior radiotherapy\n\n          -  Negative pregnancy test for pre-menopausal women\n\n        Exclusion Criteria:\n\n          -  Concomitant diseases/conditions as unstable angina, myocardial infarction,\n             symptomatic congestive heart failure or asymptomatic with left ventricular ejection\n             fraction (LVEF) \u2264 50%, dyspnea, infection by human immunodeficiency virus (HIV),\n             active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, active\n             uncontrolled infection, pleural or pericardial effusions, myopathy, limitation of the\n             patient's ability to comply with the treatment or to follow-up the protocol, any\n             other major illness\n\n          -  Histological features of neuroendocrine or bronchioalveolar differentiation.\n\n          -  Unknown epidermal growth factor receptor (EGFR)mutation status or previously known\n             EGFR mutated status in patients with adenocarcinoma.\n\n          -  Prior or concurrent invasive malignant disease, unless in complete remission for more\n             than three years.\n\n          -  Significant cancer-related weight loss (\u226510%)within four weeks prior to treatment\n             start\n\n          -  Prior treatment with docetaxel-containing therapy\n\n          -  Symptomatic, steroid-requiring or progressive central nervous system (CNS)\n             involvement\n\n          -  Paraneoplastic syndromes"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01951157", 
            "org_study_id": "PM1183-B-004-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "A - docetaxel", 
                "description": "Powder for solution for infusion", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "C - gemcitabine + lurbinectedin (PM01183)", 
                "description": "Powder for solution for infusion", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "B - lurbinectedin (PM01183)", 
                    "C - gemcitabine + lurbinectedin (PM01183)"
                ], 
                "description": "Powder for concentrate for solution for infusion", 
                "intervention_name": "Lurbinectedin (PM01183)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Docetaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized-Controlled Three-arm Phase II Study of Lurbinectedin (PM01183) Alone or In Combination With Gemcitabine and a Control Arm With Docetaxel as Second-Line Treatment in Unresectable Non-Small Cell Lung Cancer (NSCLC) Patients", 
        "overall_contact": {
            "email": "cmfernandez@pharmamar.com", 
            "last_name": "Cristian M Fern\u00e1ndez, MD", 
            "phone": "+34 91-846-6077"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The rate estimate of the percentage of patients who are alive and progression-free at 16 weeks (~4 months) after randomization", 
            "measure": "Progression-free survival rate at four months (PFS4)", 
            "safety_issue": "No", 
            "time_frame": "At month four after patient inclusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01951157"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall survival (OS) will be defined as time from the date of first infusion to the date of death or last contact", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "12 months after last patient inclusion"
            }, 
            {
                "description": "Changes of patient's quality of life followed by a lung cancer symptom scale (LCSS)questionnaire score", 
                "measure": "Information on quality of life (QoL)", 
                "safety_issue": "No", 
                "time_frame": "At screening and every three cycles"
            }, 
            {
                "description": "Potential correlations between clinical outcomes achieved with PM01183-based treatment and molecular parameters found in previous available tumor and blood samples", 
                "measure": "Pharmacogenomic (PGx)", 
                "safety_issue": "No", 
                "time_frame": "12 months after last patient inclusion"
            }
        ], 
        "source": "PharmaMar", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PharmaMar", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}